a phase 1, first in human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is consensus among academic GMP facilities and industry that identifying, hiring, and retaining qualified staff is challenging, creating a major barrier to successful GMP operations, particularly in cell and gene therapy.
“There is consensus among academic GMP facilities as well as industry that identifying, hiring, and retaining qualified staff is challenging, creating a major barrier to successful GMP operations, particularly in the cell and gene therapy field (128).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [128]
Cites
Still being checked.
Cited by
Sorted by citations
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments
Xu, J., Ding, L., Mei, J., Hu, Y., Kong, X., Dai, S., Bu, T., Xiao, Q., & Ding, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02325-5 · Cited by 394 · see citing works
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Abou-el-Enein, M., Elsallab, M., Feldman, S. A., Fesnak, A. D., Heslop, H. E., Marks, P., Till, B. G., Bauer, G., & Savoldo, B. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0084 · Cited by 321 · see citing works
CAR-engineered cell therapies: current understandings and future perspectives
Bayat, M., & Nahand, J. S. (2026) · Molecular Biomedicine · doi:10.1186/s43556-025-00401-4 · Cited by 31 · see citing works
Preclinical In Vitro and In Vivo Models for Adoptive Cell Therapy of Cancer
Kaushik, G., Venkatesha, S. H., Verma, B., Vishwakarma, B. A., Zhang, A.-H., & Wesa, A. K. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000609 · Cited by 7 · see citing works
Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor
Chen, K. M., Grun, D., Gautier, B., Venkatesha, S. H., Maddox, M., Zhang, A.-H., & Andersen, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1380065 · Cited by 5 · see citing works
- Authors
- Bauml, J., Barton, D., Ronczka, A., Cushing, D., Klichinsky, M., & Dees, E. C.
- Affiliations
- University of Pennsylvania (US)
- Carisma Therapeutics (United States) (US)
- University of North Carolina at Chapel Hill (US)
- Venue
- Cytotherapy
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 23
- Issue
- 5
- Pages
- S95-S96
- ISSN
- 1465-3249 (ISSN-L)
- OpenAlex
- W3160136151
- Cited by
- 4
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2022: 1
- FWCI
- 0.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cytotherapy (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- HER2, chimeric antigen receptor, CAR macrophages, adenoviral gene transfer, adoptive immunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
